Phemiton may be available in the countries listed below.
Methylphenobarbital is reported as an ingredient of Phemiton in the following countries:
International Drug Name Search
Nalbuphin Amomed may be available in the countries listed below.
Nalbuphine hydrochloride (a derivative of Nalbuphine) is reported as an ingredient of Nalbuphin Amomed in the following countries:
International Drug Name Search
Cholerit may be available in the countries listed below.
Pravastatin sodium salt (a derivative of Pravastatin) is reported as an ingredient of Cholerit in the following countries:
International Drug Name Search
In the US, Uprima is a member of the drug class dopaminergic antiparkinsonism agents and is used to treat Parkinson's Disease.
Apomorphine is reported as an ingredient of Uprima in the following countries:
Apomorphine hydrochloride (a derivative of Apomorphine) is reported as an ingredient of Uprima in the following countries:
International Drug Name Search
Treating acute lymphoblastic leukemia (ALL) in certain patients. It is used along with other cancer medicines.
Oncaspar is an antineoplastic agent. It works by decreasing the amount of asparagine in the body, which kills certain leukemia cells.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Oncaspar. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Oncaspar. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Oncaspar may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Oncaspar as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Oncaspar.
All medicines may cause side effects, but many people have no, or minor, side effects. No COMMON side effects have been reported with Oncaspar. Seek medical attention right away if any of these SEVERE side effects occur:
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; trouble swallowing); blurred vision or other vision changes; calf or leg pain or swelling; chest pain; confusion; coughing up blood; dizziness; one-sided weakness; pain, redness, or swelling at the injection site; severe headache; shortness of breath; severe stomach pain; slurred speech; swelling of an arm or leg; symptoms of high blood sugar (eg, increased thirst, hunger, or urination; drowsiness; flushing; rapid breathing; fruit-like breath odor); unusual bleeding or bruising; yellowing of skin or eyes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Oncaspar side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include rash.
Oncaspar is usually handled and stored by a health care provider. If you are using Oncaspar at home, store Oncaspar as directed by your pharmacist or health care provider. Keep Oncaspar out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Oncaspar. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Chlorexivet may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Chlorhexidine digluconate (a derivative of Chlorhexidine) is reported as an ingredient of Chlorexivet in the following countries:
International Drug Name Search
Cyprostat may be available in the countries listed below.
UK matches:
Cyproterone 17α-acetate (a derivative of Cyproterone) is reported as an ingredient of Cyprostat in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Aklonil may be available in the countries listed below.
Clonazepam is reported as an ingredient of Aklonil in the following countries:
International Drug Name Search
Cefalotin Sandoz may be available in the countries listed below.
Cefalotin sodium salt (a derivative of Cefalotin) is reported as an ingredient of Cefalotin Sandoz in the following countries:
International Drug Name Search
Unalium may be available in the countries listed below.
Flunarizine is reported as an ingredient of Unalium in the following countries:
International Drug Name Search
Magion may be available in the countries listed below.
Magaldrate is reported as an ingredient of Magion in the following countries:
International Drug Name Search
Petty may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Dimpylate is reported as an ingredient of Petty in the following countries:
Permethrin is reported as an ingredient of Petty in the following countries:
Piperonyl Butoxide is reported as an ingredient of Petty in the following countries:
International Drug Name Search
Sterinol may be available in the countries listed below.
Benzalkonium chloride (a derivative of Benzalkonium) is reported as an ingredient of Sterinol in the following countries:
International Drug Name Search
Vetasept may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Chlorhexidine digluconate (a derivative of Chlorhexidine) is reported as an ingredient of Vetasept in the following countries:
Povidone-Iodine is reported as an ingredient of Vetasept in the following countries:
International Drug Name Search
Hymecromome may be available in the countries listed below.
Hymecromome (BAN) is also known as Hymecromone (Rec.INN)
International Drug Name Search
Glossary
| BAN | British Approved Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Generic Name: rituximab (ri TUX i mab)
Brand Names: Rituxan
Rituximab is a cancer medication that interferes with the growth of cancer cells and slows their growth and spread in the body.
Rituximab is used in combination with other cancer medicines to treat non-Hodgkin's lymphoma or chronic lymphocytic leukemia. Rituximab is also used in combination with another drug called methotrexate to treat symptoms of adult rheumatoid arthritis.
Rituximab is also used in combination with steroid medicines to treat certain rare disorders that cause inflammation of the blood vessels.
Rituximab may also be used for purposes not listed in this medication guide.
To be sure this medication is not causing harmful effects, your blood may need to be tested often. Your kidney or liver function may also need to be tested. Visit your doctor regularly.
If you have hepatitis B you may develop liver symptoms after you stop using this medication, even months after stopping. Your doctor may want to check your liver function at regular visits for several months after you stop using rituximab. Visit your doctor regularly.
To make sure you can safely use rituximab, tell your doctor if you have any of these other conditions:
liver disease or hepatitis B (or if you are a carrier of hepatitis B);
kidney disease;
systemic lupus erythematosus (SLE);
lung disease or a breathing disorder;
a weak immune system;
a history of heart disease, angina (chest pain), or heart rhythm disorder; or
a recent or active infection, including herpes, shingles, cytomegalovirus, chickenpox, West Nile virus, hepatitis C, or any infection that keeps coming back or does not clear up.
Rituximab is injected into a vein through an IV. You will receive this injection in a clinic or hospital setting.
Before you receive rituximab, you may be given other medications to prevent certain side effects that rituximab can cause.
The medicine is usually given once per week for 4 to 8 weeks. In the treatment of rheumatoid arthritis, you may receive only two injections of rituximab, with 2 weeks in between treatments.
To be sure this medication is not causing harmful effects, your blood may need to be tested often. Your kidney or liver function may also need to be tested. Visit your doctor regularly.
If you have hepatitis B you may develop liver symptoms after you stop using this medication, even months after stopping. Your doctor may want to check your liver function at regular visits for several months after you stop using rituximab. Do not miss any scheduled visits.
Call your doctor if you miss an appointment for your rituximab injection.
Do not receive a "live" vaccine while using rituximab, and avoid coming into contact with anyone who has recently received a live vaccine. There is a chance that the virus could be passed on to you. Live vaccines include measles, mumps, rubella (MMR), Bacillus Calmette-Guérin (BCG), oral polio, rotavirus, smallpox, typhoid, yellow fever, varicella (chickenpox), H1N1 influenza, and nasal flu vaccine.
Some people receiving a rituximab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, weak, nauseated, light-headed, itchy, or if you have a fever, chills, muscle pain, sneezing, sore throat, trouble breathing, or pain in your chest or shoulders. Infusion reactions often occur within the first 24 hours after the start of your rituximab infusion.
lower back pain, blood in your urine, numbness or tingly feeling around your mouth;
urinating less than usual;
muscle weakness, tightness, or contraction, overactive reflexes;
fast or slow heart rate, weak pulse, feeling short of breath, fainting;
uneven heartbeats, wheezing or trouble breathing;
confusion, dizziness, loss of balance, sudden numbness or weakness, especially on one side of the body;
chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
fever, chills, cough, body aches, flu symptoms, ongoing cold symptoms such as stuffy nose, sneezing, sore throat;
easy bruising or bleeding;
pain or burning when you urinate;
earache, painful mouth ulcers, skin sores, warmth or swelling with skin redness;
a red, raised, blistering, scaly, itchy, or peeling skin rash;
severe constipation or stomach pain;
black, bloody, or tarry stools; or
nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).
Less serious side effects may include:
pain where the IV needle is placed;
mild stomach pain, nausea, or diarrhea;
swelling in your hands or feet;
muscle or joint pain; or
night sweats.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for non-Hodgkin's Lymphoma:
Information for all healthcare professionals administering rituximab: Do not administer as an intravenous push or bolus. Administer only as an intravenous (IV) infusion. Premedicate before each infusion with acetaminophen and an antihistamine. For RA patients, methylprednisolone 100 mg IV or its equivalent is recommended 30 minutes prior to each infusion. Pneumocystis jiroveci pneumonia (PCP) and anti-herpetic viral prophylaxis is recommended for patients with CLL during treatment and for up to 12 months following treatment as appropriate.
First Infusion: Initiate infusion at a rate of 50 mg/hr. In the absence of infusion toxicity, increase infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
Subsequent Infusions: Initiate infusion at a rate of 100 mg/hr. In the absence of infusion toxicity, increase rate by 100 mg/hr increments at 30 minute intervals, to a maximum of 400 mg/hr.
Interrupt the infusion or slow the infusion rate for infusion reactions. Continue the infusion at one-half the previous rate upon improvement of symptoms.
Relapsed or Refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's Lymphoma (NHL): 375 mg/m2 IV once weekly for 4 or 8 doses.
Retreatment for Relapsed or Refractory, low-grade or follicular, CD20-positive, B-cell NHL: 375 mg/m2 IV once weekly for 4 doses.
Previously untreated, follicular, CD20-positive, B-cell NHL: 375 mg/m2 IV, administered on Day 1 of each cycle of chemotherapy, for up to 8 doses. In patients with complete or partial response, initiate rituximab maintenance 8 weeks following completion of rituximab in combination with chemotherapy. Administer rituximab as a single agent every 8 weeks for 12 doses.
Non-progressing, Low-grade, CD20-positive, B-cell NHL, after first-line CVP chemotherapy: Following completion of 6 to 8 cycles of CVP chemotherapy, administer 375 mg/m2 IV once weekly for 4 doses at 6 month intervals to a maximum of 16 doses.
Diffuse large B-cell NHL: 375 mg/m2 IV given on day 1 of each cycle of chemotherapy for up to 8 doses.
Chronic Lymphocytic Leukemia (CLL): 375 mg/m2 the day prior to initiation of FC chemotherapy, then 500 mg/m2 on Day 1 of cycles 2 through 6 (every 28 days).
As a required component of ibritumomab tiuxetan therapeutic regimen: rituximab 250 mg/m2 should be infused within 4 hours prior to the administration of Indium-111- (In-111-) ibritumomab tiuxetan and within 4 hours prior to the administration of Yttrium-90- (Y-90-) ibritumomab tiuxetan. Administration of rituximab and In-111-ibritumomab tiuxetan should precede rituximab and Y-90-ibritumomab tiuxetan by 7 to 9 days. (Note: The ibritumomab tiuxetan therapeutic regimen is indicated for the treatment of patients with relapsed or refractory low-grade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular non-Hodgkin's lymphoma.)
Usual Adult Dose for Rheumatoid Arthritis:
Information for all healthcare professionals administering rituximab: Do not administer as an intravenous push or bolus. Administer only as an intravenous (IV) infusion. Premedicate before each infusion with acetaminophen and an antihistamine. For RA patients, methylprednisolone 100 mg IV or its equivalent is recommended 30 minutes prior to each infusion. Pneumocystis jiroveci pneumonia (PCP) and anti-herpetic viral prophylaxis is recommended for patients with CLL during treatment and for up to 12 months following treatment as appropriate.
First Infusion: Initiate infusion at a rate of 50 mg/hr. In the absence of infusion toxicity, increase infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
Subsequent Infusions: Initiate infusion at a rate of 100 mg/hr. In the absence of infusion toxicity, increase rate by 100 mg/hr increments at 30 minute intervals, to a maximum of 400 mg/hr.
Interrupt the infusion or slow the infusion rate for infusion reactions. Continue the infusion at one-half the previous rate upon improvement of symptoms.
Rheumatoid Arthritis: Rituximab is given in combination with methotrexate. Rituximab is given as two 1000 mg IV infusions separated by 2 weeks. Glucocorticoids administered as methylprednisolone 100 mg IV or its equivalent 30 minutes prior to each infusion are recommended to reduce the incidence and severity of infusion reactions. Subsequent courses should be administered every 24 weeks or based on clinical evaluation, but not sooner than every 16 weeks.
Usual Adult Dose for Chronic Lymphocytic Leukemia:
Information for all healthcare professionals administering rituximab: Do not administer as an intravenous push or bolus. Administer only as an intravenous (IV) infusion. Premedicate before each infusion with acetaminophen and an antihistamine. For RA patients, methylprednisolone 100 mg IV or its equivalent is recommended 30 minutes prior to each infusion. Pneumocystis jiroveci pneumonia (PCP) and anti-herpetic viral prophylaxis is recommended for patients with CLL during treatment and for up to 12 months following treatment as appropriate.
First Infusion: Initiate infusion at a rate of 50 mg/hr. In the absence of infusion toxicity, increase infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
Subsequent Infusions: Initiate infusion at a rate of 100 mg/hr. In the absence of infusion toxicity, increase rate by 100 mg/hr increments at 30 minute intervals, to a maximum of 400 mg/hr.
Interrupt the infusion or slow the infusion rate for infusion reactions. Continue the infusion at one-half the previous rate upon improvement of symptoms.
Chronic Lymphocytic Leukemia (CLL): 375 mg/m2 IV the day prior to the initiation of fludarabine and cyclophosphamide (FC) chemotherapy, then 500 mg/m2 on Day 1 of cycles 2 to 6 (every 28 days).
Pneumocystis jiroveci pneumonia (PCP) and anti-herpetic viral prophylaxis is recommended for patients with CLL during treatment and for up to 12 months following treatment as appropriate.
Usual Adult Dose for Wegener's Granulomatosus:
Information for all healthcare professionals administering rituximab: Do not administer as an intravenous push or bolus. Administer only as an intravenous (IV) infusion. Premedicate before each infusion with acetaminophen and an antihistamine. For RA patients, methylprednisolone 100 mg IV or its equivalent is recommended 30 minutes prior to each infusion. Pneumocystis jiroveci pneumonia (PCP) and anti-herpetic viral prophylaxis is recommended for patients with CLL during treatment and for up to 12 months following treatment as appropriate.
First Infusion: Initiate infusion at a rate of 50 mg/hr. In the absence of infusion toxicity, increase infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
Subsequent Infusions: Initiate infusion at a rate of 100 mg/hr. In the absence of infusion toxicity, increase rate by 100 mg/hr increments at 30 minute intervals, to a maximum of 400 mg/hr.
Interrupt the infusion or slow the infusion rate for infusion reactions. Continue the infusion at one-half the previous rate upon improvement of symptoms.
Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA): 375 mg/m2 IV administered once weekly for 4 weeks.
Glucocorticoids administered as methylprednisolone 1000 mg IV daily for 1 to 3 days followed by oral prednisone 1 mg/kg/day (not to exceed 80 mg/day and tapered per clinical need) are recommended to treat severe vasculitis symptoms. This regimen should begin within 14 days prior to or with the initiation of rituximab and may continue during and after the 4 week course of rituximab treatment.
Safety and efficacy of treatment with subsequent courses of rituximab have not been established.
PCP prophylaxis is recommended for patients with WG and MPA during treatment and for at least 6 months following the last rituximab infusion.
Usual Adult Dose for Microscopic Polyangiitis:
Information for all healthcare professionals administering rituximab: Do not administer as an intravenous push or bolus. Administer only as an intravenous (IV) infusion. Premedicate before each infusion with acetaminophen and an antihistamine. For RA patients, methylprednisolone 100 mg IV or its equivalent is recommended 30 minutes prior to each infusion. Pneumocystis jiroveci pneumonia (PCP) and anti-herpetic viral prophylaxis is recommended for patients with CLL during treatment and for up to 12 months following treatment as appropriate.
First Infusion: Initiate infusion at a rate of 50 mg/hr. In the absence of infusion toxicity, increase infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
Subsequent Infusions: Initiate infusion at a rate of 100 mg/hr. In the absence of infusion toxicity, increase rate by 100 mg/hr increments at 30 minute intervals, to a maximum of 400 mg/hr.
Interrupt the infusion or slow the infusion rate for infusion reactions. Continue the infusion at one-half the previous rate upon improvement of symptoms.
Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA): 375 mg/m2 IV administered once weekly for 4 weeks.
Glucocorticoids administered as methylprednisolone 1000 mg IV daily for 1 to 3 days followed by oral prednisone 1 mg/kg/day (not to exceed 80 mg/day and tapered per clinical need) are recommended to treat severe vasculitis symptoms. This regimen should begin within 14 days prior to or with the initiation of rituximab and may continue during and after the 4 week course of rituximab treatment.
Safety and efficacy of treatment with subsequent courses of rituximab have not been established.
PCP prophylaxis is recommended for patients with WG and MPA during treatment and for at least 6 months following the last rituximab infusion.
Tell your doctor about all other medicines you use, especially:
cisplatin (Platinol);
adalimumab (Humira);
auranofin (Ridaura);
azathioprine (Imuran);
cyclosporine (Gengraf, Neoral, Sandimmune);
etanercept (Enbrel);
infliximab (Remicade);
leflunomide (Arava);
minocycline (Dynacin, Minocin, Vectrin);
sulfasalazine (Azulfidine);
blood pressure medications; or
medication to treat malaria, such as chloroquine (Aralen) or hydroxychloroquine (Plaquenil, Quineprox).
This list is not complete and other drugs may interact with rituximab. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
See also: rituximab side effects (in more detail)
Adrenalin-Braun may be available in the countries listed below.
Epinephrine hydrochloride (a derivative of Epinephrine) is reported as an ingredient of Adrenalin-Braun in the following countries:
International Drug Name Search
